Advanced abdominal cancers can be complex and emotionally overwhelming, especially when the disease spreads to the lining of the abdomen. In recent years, HIPEC (Hyperthermic Intraperitoneal Chemotherapy) has emerged as an advanced treatment option that combines surgery with targeted heated chemotherapy to improve outcomes in selected patients.
In this complete guide, Dr. Deepak Chhabra explains how HIPEC works, who may benefit from it, potential risks, recovery expectations, and how this treatment is used in managing conditions such as ovarian cancer, appendix tumors, and peritoneal surface malignancies in Mumbai.
HIPEC stands for Hyperthermic Intraperitoneal Chemotherapy — a specialized cancer treatment for advanced abdominal cancers. The procedure combines surgery with heated chemotherapy delivered directly inside the abdominal cavity to target microscopic cancer cells that may remain after tumor removal.
Traditional chemotherapy circulates throughout the body, affecting both cancerous and healthy cells. In contrast, HIPEC delivers a heated chemotherapy solution locally, allowing:
This approach makes Hyperthermic intraperitoneal chemotherapy (HIPEC) a highly effective treatment option for complex abdominal cancers that cannot be completely removed by surgery alone.
HIPEC is always performed with cytoreductive surgery (CRS), often referred to as CRS + HIPEC.
During CRS, the surgeon removes all visible tumors from the abdominal cavity. This may involve removing parts of organs, peritoneal tissue, and other affected structures. The primary goal is to reduce tumor burden to the smallest possible level, often microscopic.
After CRS, the abdomen is filled with a warm chemotherapy solution, typically heated to 41–42°C (105–108°F). The heat improves chemotherapy effectiveness and helps the drugs penetrate remaining cancer cells. The solution circulates throughout the abdomen for 60–90 minutes, targeting microscopic cancer cells that could cause recurrence.
Key points about HIPEC:
HIPEC is particularly effective for cancers that either originate in or spread to the abdominal lining. These include:
Because HIPEC targets the entire abdominal cavity, it is not typically used for cancers that have spread to distant organs such as the lungs or liver.
HIPEC offers several advantages over conventional chemotherapy:
High doses of chemotherapy are delivered directly to the cancer-affected area, improving exposure to residual cancer cells while limiting systemic toxicity.
Warm chemotherapy increases tissue penetration and cancer cell death, which standard IV chemotherapy does not provide.
Because HIPEC is confined to the abdominal cavity, common chemotherapy side effects, such as hair loss or nausea, may be less pronounced.
Clinical observations suggest HIPEC may improve survival and reduce recurrence in selected conditions like pseudomyxoma peritonei and certain colorectal cancers.
Like all major surgeries, HIPEC carries potential risks, including:
The overall risk depends on the type and extent of cancer, the patient’s general health, and how extensive the surgery needs to be. Patients should discuss the potential benefits and limitations with their surgical oncologist.
Recovery from HIPEC and CRS is significant due to the combination of major surgery and chemotherapy. Typical expectations include:
Most patients gradually return to normal activities over weeks to months, depending on overall health and disease severity. Nutritional support and rehabilitation often form important parts of recovery.
Not all patients with abdominal cancer are suitable. Factors considered include:
Patients with peritoneal surface tumors may benefit from specialized HIPEC procedures. A thorough evaluation by a surgical oncology expert, such as Dr. Deepak Chhabra, who regularly operates at Lilavati Hospital and Research Centre, Mumbai, can determine if HIPEC is appropriate for an individual’s condition.
In select cases, HIPEC may be performed more than once, particularly if cancer recurs or initial cytoreduction was incomplete. Each case is evaluated individually.
HIPEC is not a universal cure but can significantly improve outcomes and reduce recurrence risk when combined with cytoreductive surgery.
The entire procedure can last several hours: cytoreductive surgery is extensive, followed by 60–90 minutes for heated chemotherapy.
Some of the best response rates are seen in pseudomyxoma peritonei and appendiceal cancers, though outcomes vary based on cancer type and individual health.
Post-surgery, maintaining a balanced diet, staying hydrated, and following the rehabilitation plan prescribed by your oncology team supports recovery.
Yes, in some cases HIPEC is combined with targeted therapy or post-operative chemotherapy. This is decided based on tumor type, spread, and patient health.
Stay up-to-date with the latest developments in cancer research, treatment, and patient stories through our curated collection of cancer blogs and news articles. From breakthrough discoveries to inspiring survivor journeys.
Discover first hand accounts from patients who have experienced compassionate care and expert treatment at our clinic. Read their reviews to get to know their journey.
5 Out of 5 from 92 Reviews
VIDEO CONSULTATION
Phone Calls
Physical visit